Positron Emission Tomography/Computed Tomography: The Current Technology and Applications

Radiologic Clinics of North America

Volumn 47, Issue 1, 2009, Pages 147-160

  Mittra, Erik ^a   Quon, Andrew ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiology; Fluorodeoxyglucose; Infection and inflammation; Neurology; Novel radiopharmaceuticals; Oncology; Physics; Positron emission tomography

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; GLUCOSE; IODINATED CONTRAST MEDIUM; NITROGEN 13; OXYGEN 15;

ALGORITHM; ANATOMY; ATTENUATION; BREAST; BREAST CANCER; CARDIOLOGY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; COST; CRYSTAL STRUCTURE; DEMENTIA; DEVICE; ELECTRONICS; ENTERITIS; ESOPHAGUS CANCER; GLUCOSE METABOLISM; HEAD AND NECK CANCER; HUMAN; IMAGE QUALITY; IMAGE RECONSTRUCTION; INFECTION; INFLAMMATION; LIGHT; LIVER CELL CARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; LUNG METASTASIS; LUNG NODULE; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDIASTINUM METASTASIS; MELANOMA; NEUROLOGY; NOISE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OSTEOARTHRITIS; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PHOTON; PHYSICS; PIGMENTED VILLONODULAR SYNOVITIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SEIZURE; STRENGTH; SUBACUTE THYROIDITIS; THYROID CANCER; TREATMENT PLANNING; UTERINE CERVIX CANCER; VASCULITIS;

CONTRAST MEDIA; EQUIPMENT DESIGN; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMAGE PROCESSING, COMPUTER-ASSISTED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 58949090833     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2008.10.005     Document Type: Review

References (53)

1. Pichler B.J., Wehrl H.F., Judenhofer M.S., et al. Latest advances in molecular imaging instrumentation. J Nucl Med 49 Suppl 2 (2008) 5S-23S
2. Yang Y., Wu Y., Qi J., et al. A prototype PET scanner with DOI-encoding detectors. J Nucl Med 49 7 (2008) 1132-1140
3. McCallum S., Clowes P., Welch A., et al. A four-layer attenuation compensated PET detector based on APD arrays without discrete crystal elements. Phys Med Biol 50 17 (2005) 4187-4207
4. Pichler B.J., Swann B.K., Rochelle J., et al. Lutetium oxyorthosilicate block detector readout by avalanche photodiode arrays for high resolution animal PET. Phys Med Biol 49 18 (2004) 4305-4319
5. Pichler B.J., Judenhofer M.S., Catana C., et al. Performance test of an LSO-APD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med 47 4 (2006) 639-647
6. Karp J.S., Surti S., Daube-Witherspoon M.E., et al. Benefit of time-of-flight in PET: experimental and clinical results. J Nucl Med 49 3 (2008) 462-470
7. Surti S., Karp J.S., Popescu L.M., et al. Investigation of time-of-flight benefit for fully 3-D PET. IEEE Trans Med Imaging 25 5 (2006) 529-538
8. Defrise M., and Gullberg G.T. Image reconstruction. Phys Med Biol 51 13 (2006) R139-R154
9. Tarantola G., Zito F., Gerundini P., et al. PET instrumentation and reconstruction algorithms in whole-body applications. J Nucl Med 44 5 (2003) 756-769
10. De Bernardi E., Zito F., Baselli G., et al. Assessment of PSF modeling in PET AWOSEM reconstruction. Conf Proc IEEE Eng Med Biol Soc 2007 (2007) 6548-6551
11. Gould M.K., Maclean C.C., Kuschner W.G., et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. J Am Med Assoc 285 7 (2001) 914-924
12. Gould M.K., Kuschner W.G., Rydzak C.E., et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 139 11 (2003) 879-892
13. Wallace M.B., Nietert P.J., Earle C., et al. An analysis of multiple staging management strategies for carcinoma of the esophagus: computed tomography, endoscopic ultrasound, positron emission tomography, and thoracoscopy/laparoscopy. Ann Thorac Surg 74 4 (2002) 1026-1032
14. Brucher B.L., Weber W., Bauer M., et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233 3 (2001) 300-309
15. Esteves F.P., Schuster D.M., Halkar R.K., et al. Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med 36 2 (2006) 169-181
16. Pelosi E., and Deandreis D. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer. Eur J Surg Oncol 33 1 (2007) 1-6
17. Soyka J.D., Veit-Haibach P., Strobel K., et al. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?. J Nucl Med 49 3 (2008) 354-361
18. Wiering B., Ruers T.J., Oyen W.J., et al. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases. Expert Rev Anticancer Ther 4 4 (2004) 607-613
19. Lubezky N., Metser U., Geva R., et al. The role and limitations of 18-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 11 4 (2007) 472-478
20. Swetter S.M., Carroll L.A., Johnson D.L., et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 9 7 (2002) 646-653
21. Wagner J.D., Schauwecker D., Davidson D., et al. Inefficacy of F-18 fluorodeoxy-d-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 104 3 (2005) 570-579
22. Belhocine T., Pierard G., De Labrassinne M., et al. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 7 4 (2002) 271-278
23. Fink A.M., Holle-Robatsch S., Herzog N., et al. Positron emission tomography is not useful in detecting metastasis in the sentinel lymph node in patients with primary malignant melanoma stage I and II. Melanoma Res 14 2 (2004) 141-145
24. Stas M., Stroobants S., Dupont P., et al. 18-FDG PET scan in the staging of recurrent melanoma: additional value and therapeutic impact. Melanoma Res 12 5 (2002) 479-490
25. Pelosi E., Pregno P., Penna D., et al. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Radiol Med 113 4 (2008) 578-590
26. Altamirano J., Esparza J.R., de la Garza Salazar J., et al. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET. Arch Med Res 39 1 (2008) 69-77
27. Yamazaki Y., Saitoh M., Notani K., et al. Assessment of cervical lymph node metastases using FDG-PET in patients with head and neck cancer. Ann Nucl Med 22 3 (2008) 177-184
28. Murakami R., Uozumi H., Hirai T., et al. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 68 2 (2007) 377-382
29. Jeong H.S., Baek C.H., Son Y.I., et al. Use of integrated 18F-FDG PET/CT to improve the accuracy of initial cervical nodal evaluation in patients with head and neck squamous cell carcinoma. Head Neck 29 3 (2007) 203-210
30. Schoder H., Carlson D.L., Kraus D.H., et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 47 5 (2006) 755-762
31. Yen T.C., Chang J.T., Ng S.H., et al. Staging of untreated squamous cell carcinoma of buccal mucosa with 18F-FDG PET: comparison with head and neck CT/MRI and histopathology. J Nucl Med 46 5 (2005) 775-781
32. Krabbe C.A., Pruim J., van der Laan B.F., et al. FDG-PET and detection of distant metastases and simultaneous tumors in head and neck squamous cell carcinoma: a comparison with chest radiography and chest CT. Oral Oncol (2008) [epub ahead of print]
33. Tan A., Adelstein D.J., Rybicki L.A., et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg 133 5 (2007) 435-440
34. Raylman R.R., Majewski S., Smith M.F., et al. The positron emission mammography/tomography breast imaging and biopsy system (PEM/PET): design, construction and phantom-based measurements. Phys Med Biol 53 3 (2008) 637-653
35. Buscombe J.R., Holloway B., Roche N., et al. Position of nuclear medicine modalities in the diagnostic work-up of breast cancer. Q J Nucl Med Mol Imaging 48 2 (2004) 109-118
36. Byrne A.M., Hill A.D., Skehan S.J., et al. Positron emission tomography in the staging and management of breast cancer. Br J Surg 91 11 (2004) 1398-1409
37. Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 23 8 (2005) 1601-1602
38. Isasi C.R., Moadel R.M., Blaufox M.D., et al. A meta-analysis of FDG-PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Res Treat 90 2 (2005) 105-112
39. Quon A., and Gambhir S.S. FDG-PET and beyond: molecular breast cancer imaging. J Clin Oncol 23 8 (2005) 1664-1673
40. Rieber A., Schirrmeister H., Gabelmann A., et al. Pre-operative staging of invasive breast cancer with MR mammography and/or PET: boon or bunk?. Br J Radiol 75 898 (2002) 789-798
41. Zangheri B., Messa C., Picchio M., et al. PET/CT and breast cancer. Eur J Nucl Med Mol Imaging 31 Suppl 1 (2004) S135-S142
42. Flanagan F.L., Dehdashti F., Siegel B.A., et al. PET in breast cancer. Semin Nucl Med 28 4 (1998) 290-302
43. Bombardieri E., and Crippa F. PET imaging in breast cancer. Q J Nucl Med 45 3 (2001) 245-256
44. Vranjesevic D., Filmont J.E., Meta J., et al. Whole-body (18)F-FDG PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med 43 3 (2002) 325-329
45. Sawada S.G., Allman K.C., Muzik O., et al. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects. J Am Coll Cardiol 23 1 (1994) 92-98
46. Marin-Neto J.A., Dilsizian V., Arrighi J.A., et al. Thallium scintigraphy compared with 18F-fluorodeoxyglucose positron emission tomography for assessing myocardial viability in patients with moderate versus severe left ventricular dysfunction. Am J Cardiol 82 9 (1998) 1001-1007
47. Bonow R.O., and Dilsizian V. Thallium 201 for assessment of myocardial viability. Semin Nucl Med 21 3 (1991) 230-241
48. Namdar M., Hany T.F., Koepfli P., et al. Integrated PET/CT for the assessment of coronary artery disease: a feasibility study. J Nucl Med 46 6 (2005) 930-935
49. Berman D.S., Hachamovitch R., Shaw L.J., et al. Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: assessment of patients with suspected coronary artery disease. J Nucl Med 47 1 (2006) 74-82
50. Di Carli M.F., Dorbala S., Curillova Z., et al. Relationship between CT coronary angiography and stress perfusion imaging in patients with suspected ischemic heart disease assessed by integrated PET-CT imaging. J Nucl Cardiol 14 6 (2007) 799-809
51. Koeppe R.A., Gilman S., Junck L., et al. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography. Alzheimers Dement 4 1 Suppl 1 (2008) S67-S76
52. Kaim A. Sterile inflammatory disease. In: Schulthess G.K.V. (Ed). Clinical molecular anatomic imaging. 2 edition (2003), Lippincott Williams & Wilkins, Philadelphia 429-437
53. Meller J., Sahlmann C.O., Scheel A.K., et al. 18F-FDG PET and PET/CT in fever of unknown origin. J Nucl Med 48 1 (2007) 35-45